Emergent BioSolutions' (EBS) Buy Rating Reiterated at HC Wainwright

Emergent BioSolutions (NYSE:EBS - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 160.19% from the stock's current price. HC Wainwright also issued estimates for Emergent BioSolutions' Q1 2025 earnings at $0.27 EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

EBS has been the subject of a number of other research reports. StockNews.com raised shares of Emergent BioSolutions from a "hold" rating to a "buy" rating in a research note on Monday, February 17th. Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 1.3 %

Shares of EBS stock traded down $0.08 on Tuesday, reaching $5.77. 936,078 shares of the company's stock traded hands, compared to its average volume of 2,654,028. The company has a market capitalization of $312.37 million, a P/E ratio of -1.41 and a beta of 1.62. Emergent BioSolutions has a 12-month low of $1.82 and a 12-month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The business's 50 day moving average price is $9.38 and its two-hundred day moving average price is $9.00.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to analysts' expectations of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the previous year, the business posted ($0.77) EPS. On average, equities analysts forecast that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Covestor Ltd lifted its stake in shares of Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Emergent BioSolutions during the fourth quarter valued at about $63,000. E Fund Management Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $98,000. EP Wealth Advisors LLC bought a new stake in shares of Emergent BioSolutions during the 4th quarter worth about $110,000. Finally, Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions during the 3rd quarter valued at about $96,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.